Printed From:

Proven safety and tolerability1

  • Incidence of hypoglycemia in adult patients with T2DM treated with SOLIQUA 100/33

NO CLINICALLY IMPORTANT DIFFERENCES IN RISK OF SEVERE AND DOCUMENTED SYMPTOMATIC HYPOGLYCEMIA BETWEEN SOLIQUA 100/33 AND COMPARATORS WERE OBSERVED IN CLINICAL TRIALS*

*The hypoglycemia rates in these clinical trials may not be representative of hypoglycemia rates that occur in actual clinical practice.

Severe symptomatic hypoglycemia defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

Documented symptomatic hypoglycemia defined as an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value equal to or less than 70 mg/dL.

  • Treatment-emergent adverse events (with frequency ≥5%) in 2 pooled clinical trials

DISCONTINUATION DUE TO GI EVENTS IN CLINICAL TRIALS: 1.1%2

§ Gastrointestinal adverse reactions occur more frequently at the beginning of therapy.1

  • 3 lbs was the mean difference between the treatment arms at Week 30 (+1.5 lbs for insulin glargine vs -1.5 lbs for SOLIQUA 100/33).2 The clinical relevance of this finding is unclear
  • Weight gain can occur with insulin-containing products, including SOLIQUA 100/33, and has been attributed to the anabolic effects of insulin1